Ganstigmine (hydrochloride)

Ganstigmine hydrochloride (CHF 2819) is an orally active AChE inhibitor. Ganstigmine hydrochloride promotes the release of sAPPα from neuroblastoma cells. Ganstigmine hydrochloride increases the concentration of acetylcholine in the prefrontal cortex of rats. Ganstigmine hydrochloride is used in research on neurological diseases such as Alzheimer's disease[1][2].

Product Specifications

CAS Number

[412044-92-9]

Product Name Alternative

CHF 2819

UNSPSC

12352005

Target

Cholinesterase (ChE)

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Smiles

O=C(OC1=CC2=C(N[C@]3([H])[C@@]2(C)CC[N@+]3([O-])C)C=C1)NC4=CC=CC=C4CC.Cl

Molecular Formula

C21H26ClN3O3

Molecular Weight

403.90

References & Citations

[1]Trabace L, et al. Neurochemical and neurobehavioral effects of ganstigmine (CHF2819), a novel acetylcholinesterase inhibitor, in rat prefrontal cortex: an in vivo study. Pharmacol Res. 2007 Oct;56 (4) :288-94.|[2]Mazzucchelli M, et al. Characterization of the effect of ganstigmine (CHF2819) on amyloid precursor protein metabolism in SH-SY5Y neuroblastoma cells. J Neural Transm (Vienna) . 2003 Aug;110 (8) :935-47.